trametinib

Known as: N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide, Trametinibum 
An orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MEK MAPK/ERK kinase) with potential antineoplastic activity. Trametinib… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2017
Highly Cited
2017
BACKGROUND Combination therapy with the BRAF inhibitor dabrafenib plus the MEK inhibitor trametinib improved survival in patients… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2015
Highly Cited
2015
BACKGROUND The BRAF inhibitors vemurafenib and dabrafenib have shown efficacy as monotherapies in patients with previously… (More)
Is this relevant?
Highly Cited
2015
Highly Cited
2015
BACKGROUND Previously, a study of ours showed that the combination of dabrafenib and trametinib improves progression-free… (More)
Is this relevant?
Highly Cited
2015
Highly Cited
2015
PURPOSE To evaluate dabrafenib, a selective BRAF inhibitor, combined with trametinib, a selective MEK inhibitor, in patients with… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND Combined BRAF and MEK inhibition, as compared with BRAF inhibition alone, delays the emergence of resistance and… (More)
  • table 1
  • figure 2
  • table 2
  • table 3
  • table 3
Is this relevant?
Highly Cited
2014
Highly Cited
2014
One-third of BRAF-mutant metastatic melanoma patients treated with combined BRAF and MEK inhibition progress within 6 months… (More)
  • table 1
  • figure 1
  • figure 3
  • figure 2
  • figure 4
Is this relevant?
Highly Cited
2013
Highly Cited
2013
PURPOSE BRAF mutations promote melanoma cell proliferation and survival primarily through activation of MEK. The purpose of this… (More)
Is this relevant?
Highly Cited
2012
Highly Cited
2012
BACKGROUND Resistance to therapy with BRAF kinase inhibitors is associated with reactivation of the mitogen-activated protein… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
Is this relevant?
Highly Cited
2012
Highly Cited
2012
BACKGROUND Activating mutations in serine-threonine protein kinase B-RAF (BRAF) are found in 50% of patients with advanced… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
Highly Cited
2012
Highly Cited
2012
BACKGROUND Inhibition of MEK stops cell proliferation and induces apoptosis; therefore, this enzyme is a key anticancer target… (More)
  • table 2
  • table 1
  • table 3
  • table 4
  • figure 1
Is this relevant?